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Abstract
Background: Influenza virus remains a significant health and social concern in part because of newly emerging strains, such
as avian H5N1 virus. We have developed a prototype H5N1 vaccine using a recombinant, replication-competent Adenovirus
serotype 4 (Ad4) vector, derived from the U.S. military Ad4 vaccine strain, to express the hemagglutinin (HA) gene from A/
Vietnam/1194/2004 influenza virus (Ad4-H5-Vtn). Our hypothesis is that a mucosally-delivered replicating Ad4-H5-Vtn
recombinant vector will be safe and induce protective immunity against H5N1 influenza virus infection and disease
pathogenesis.
Methodology/Principal Findings: The Ad4-H5-Vtn vaccine was designed with a partial deletion of the E3 region of Ad4 to
accommodate the influenza HA gene. Replication and growth kinetics of the vaccine virus in multiple human cell lines
indicated that the vaccine virus is attenuated relative to the wild type virus. Expression of the HA transgene in infected cells
was documented by flow cytometry, western blot analysis and induction of HA-specific antibody and cellular immune
responses in mice. Of particular note, mice immunized intranasally with the Ad4-H5-Vtn vaccine were protected against
lethal H5N1 reassortant viral challenge even in the presence of pre-existing immunity to the Ad4 wild type virus.
Conclusions/Significance: Several non-clinical attributes of this vaccine including safety, induction of HA-specific humoral
and cellular immunity, and efficacy were demonstrated using an animal model to support Phase 1 clinical trial evaluation of
this new vaccine.
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Introduction
Since 1996, it has been reported that several novel avian
subtypes, H5N1, H7N1, H7N2, H7N3, H7N7 and H9N2 have
crossed the species barrier from domestic poultry to humans and
caused a spectrum in severity of human disease, including fatalities
[1,2,3,4]. H5N1 influenza virus is of special concern due to several
factors including its endemic hold in poultry populations in
Southeast Asia, a spread to at least 60 countries, and a case fatality
rate of more than 50% upon transmission to humans [5]. At
present, transmission among humans is rare but there is the
potential for mutational events and/or genetic re-assortment
which could result in the evolution of a highly virulent pandemic
strain with potentially greater loss of life [6]. The recent outbreak
and subsequent pandemic caused by a swine-origin H1N1
influenza virus highlights the real danger regarding emergence
of novel influenza strains. Thus, the need for effective influenza
vaccines remains a recognized global imperative.
Currently, the only U.S. approved stockpiled H5N1 influenza
vaccine is based on virus propagated in embryonated chicken eggs.
Several issues limit the effective use of inactivated H5N1 influenza
vaccines generated using this strategy: 1) reliance on embryonated
chicken eggs; 2) safety concerns of the H5N1 influenza virus grown
in bulk before inactivation [7]; 3) delivery of the vaccine by needle;
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responses in naı ¨ve individuals. The current stockpile consists of a
vaccine to A/Viet Nam/1194/2004 which is a clade 1 virus.
Circulating strains have evolved over time and moved on from
clade 1 such that it is entirely possible that the current vaccine
would be ineffective against a new emerging strain. Our Ad4
system has the advantage that it can be rapidly switched to another
HA type to meet the challenge of an emerging pandemic strain.
We sought to address these concerns and thus based our H5N1
influenza vaccine development on the live, replication-competent,
orally administered U.S. military adenovirus serotype 4 (Ad4)
vaccine which was administered to more than 10 million U.S.
recruits between 1971 and 1999 and shown to be very well
tolerated and safe [8,9,10]. Importantly, the Ad4 U.S. Military
vaccine protects against Ad4 respiratory disease confirming that
oral delivery and in vivo replication induce protective immunity
against respiratory exposure to adenovirus. This highlights the use
of the Ad4 vector platform for vaccine development as having
several attributes of an ‘ideal’ vaccine including; safety, delivery
without hypodermic syringe and relatively low cost of goods. Also
of importance, in the case of influenza pandemics, is the capacity
to readily construct adenovirus recombinant vectors encoding
genes from newly emerging pandemic viruses to meet vaccine
demands of a global threat. Additionally, delivery to and
utilization of adenovirus recombinant vector vaccines in remote
locations without the aid of cold storage may be feasible. Studies
by Alcock and colleagues [11] demonstrated that when adenovirus
was slowly dried in the presence of certain sugars, the resulting
formulation could then be stored for 6 months, at up to 45uC, with
minimal viability loses. Clinical trial evaluation will be required to
evaluate other ideal parameters such as induction of protective
immune responses following only one immunization.
Adenoviruses (Ad) are non-enveloped DNA viruses that have
been extensively studied as recombinant vector vaccines for
various viral, bacterial and parasitic disease agents or indications
including; HIV, Dengue, Rabies, Ebola, Japanese Encephalitis
virus, HBV, Streptococcus pneumonia, Tuberculosis, and Malaria
[12,13,14,15,16,17,18,19,20,21,22]. Several attributes of the Ad
vector make it potentially useful for vaccine development: 1)
growth to high titer in cell culture, especially A549 cells; 2) ability
to infect dividing and non-dividing host cells; and 3) stimulation of
both the innate and adaptive immune systems via induction of
pro-inflammatory cytokines and chemokines [23,24,25,26,27,28].
Studies using non-replicating Ad-vectored influenza vaccines have
demonstrated the utility of this approach with documented levels
of immunogenicity and efficacy using animal models
[29,30,31,32,33,34,35]. It should be noted that there are potential
limitations for use of adenovirus vectors in vaccine development. A
common concern is the existence of pre-existing antibodies to
adenovirus, likely due to exposure during childhood and
development of neutralizing antibodies against several adenovi-
ruses, which could inhibit transgene-specific immune responses
[36]. In regard to use of replicating adenoviruses as vaccine
vectors, there are restrictions such as a limited cloning capacity of
3 to 4 kb for transgene inserts [37].
As the next step in the development of influenza vaccines, we
anticipated that the use of mucosally-delivered, replication-
competent Ad4 vectored vaccines would have advantages relative
to non-replicating Ad vectored vaccines including: 1) use of lower
doses; 2) simulation of natural infection and thus induction of
potent immune system responses (innate, humoral and cellular)
and 3) induction of immunological memory [28,37,38,39,40].
In this pre-clinical study, an experimental replicating Ad4-H5-
Vtn influenza virus vaccine was designed, produced, and
evaluated for safety, immunogenicity and efficacy using an
established murine model with the goal of generating data to
support Phase 1 clinical trial evaluation of this vaccine.
Materials and Methods
Ethics Statement
All animal procedures were performed at Absorption Systems,
San Diego CA. The Institutional Animal Care and Use
Committee at Absorption Systems approved this study (Protocol
#VC-11-08-139). Murine studies were completed in accordance
with the NIH ‘‘Guide for the Care and Use of Laboratory
Animals.’’ Absorption Systems has the following accreditations:
Association for Assessment and Accreditation of Laboratory
Animal Care, NIH Assurance # A4282-01, USDA Registration
# 93-R-0444.
Cell lines
The type and source of the cell lines used are as follows: A549
(human epithelial lung carcinoma cell line; ATCC #CCL-185,
Manassas, VA); MRC-5 (human embryonic lung fibroblast cell
line; ATCC #CCL-171); HepG2 (human hepatocellular carcino-
ma cell line; ATCC #HB-8065); Hu Tu 80 (human duodenum
adenocarcinoma cell line; ATCC #HTB-40); H1299 (human lung
carcinoma cell line; ATCC #CRL-5803); and MDCK cells
(canine kidney cell line; ATCC #CCL-34).
Construction, Production and Purification of Ad4-H5-Vtn
Vector Virus
Bacterial recombination was used to generate the recombinant
Ad4-H5-Vtn vaccine virus from a plasmid that contains the
complete Ad4 genome derived from the Ad4 military vaccine
(accession # AY594254). A shuttle plasmid was constructed with
sufficient flanking Ad4 sequences to allow homologous recombi-
nation into the E3 region of the Ad4 plasmid. To incorporate the
expression cassette for the H5-Vtn HA transgene (accession #
EF541402), a partial deletion was made in the E3 which removed
the coding regions for the unknown E3 24.8K, 6.8K and 29.7K
ORFs (Figure 1A). The endogenous splice acceptor of E3 24.8K
was left in place to facilitate the expression of H5-Vtn HA from the
endogenous Major Late promoter (Figure 1A). The expression
cassette consisted of several elements. The synthetic H5-Vtn HA
gene was produced using the native DNA coding sequence but
with the polybasic cleavage site removed (Figure 1B), consistent
with the current vaccine strains, and included the 24.8K splice
acceptor upstream of the coding region. The expression cassette
included an Ad5-derived E3A polyadenylation signal sequence
downstream of the HA coding sequence to define the boundary of
early and late gene products from E3.
For homologous recombination; the full length Ad4 plasmid was
linearized in the E3 region and the Ad4-flanked expression
cassette fragment from the shuttle plasmid were combined and
used to transform BJ5183 recombination-competent bacteria cells
(Stratagene, La Jolla, CA). Clones were screened by restriction
enzyme digestion and retransformed into Top10 cells for DNA
production. The final clones of pAd4-H5-Vtn were rescreened by
restriction digest and confirmed by DNA sequencing.
To produce virus for characterization; pAd4-H5-Vtn DNA was
linearized with PacI to excise the bacterial sequences and
transfected into A549 cells using Fugene HD transfection reagent
under the standard recommended conditions. Once a cytopathic
effect (CPE) was observed, generally 7–10 days after transfection,
virus was harvested by scraping followed by 3 cycles of freeze-thaw
cell disruption of the cell pellet. The lysate was clarified by
Ad4 H5HA Avian Influenza Vaccine Development
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supernatant collected. The virus was further expanded in A549
cells twice to generate sufficient virus for viral particle titer
determination by HPLC [41]. Identity was confirmed by Western
blot to evaluate transgene-specific protein expression and DNA
sequencing of the E3 region. An additional expansion of the viral
vector was accomplished using 10-Chamber cellSTACKSH
(CorningH, Lowell, MA). The expanded virus was purified from
the resulting crude lysate, following clarification, by anion
exchange chromatography [41]. Typical virus yields were
1610
13 total purified Ad4-H5-Vtn viral particles from a single
cellSTACK; with an average viral particle to infectious titer
(TCID50) of 300:1 or less. Purified virus was recovered in a Tris-
glycerol buffer and stored at 280uC. Purified virus was used for all
in vivo mouse experiments.
Characterization of H5-Vtn HA expression
Translation of the H5-Vtn HA transgene was measured by
Western Blot and flow cytometry. Ad4-H5-Vtn recombinant virus
was serially-passaged 15 times in A549 cells to evaluate stability of
transgene expression over time. Western blots were performed
using Ad4-H5-Vtn infected A549 cells harvested when maximal
CPE was observed. Cell lysate was produced using RIPA buffer
(Thermo Scientific, Pittsburgh, PA) and assayed using Influenza
A/Vietnam/1194/04 HA antiserum (NIBRG-14, NIBSC, U.K.)
at a dilution of 1:1,000. b-actin was assayed similarly using the
Abcam antibody (Cambridge, MA) at a dilution of 1:8,000.
For flow cytometry, A549 cells infected with Ad4-H5-Vtn were
recovered after 48 hours and washed twice prior to labeling using
an anti-H5HA specific monoclonal antibody (Advanced Immuno-
chemical, Long Beach, CA). The cells were washed 2 times with
FACS buffer, re-suspended in 100 mL goat anti-IgG PE secondary
antibody (Southern Biotech, Birmingham, AL) and incubated in the
dark at 4uC for 20 minutes. The cells were washed and re-
suspended in 150 mL fixation buffer (CytoFix
TM, BD Biosciences)
prior to analysis using a flow cytometer. Acquired sample data were
analyzed using FlowJo software (Tree-Star, Inc, Ashland, OR).
One-Step Growth Curve Analysis
Attenuation of Ad4 growth resulting from the insertion of the
transgene was determined using single-step growth curves. There
are three distinct sections to this procedure: 1) culture of human
cell lines; 2) viral infection of human cell lines and 3) determination
of viral growth by infectivity titering assay. Human cell lines
(A549, MRC-5, HuTu80, HepG2 and H1299) were grown in
various media as recommended by ATCC. Cells were harvested
and plated (4610
5 cells/well in a 6-well plate, 2 mL volume/well)
in culture media. Cells were infected when 50 to 70% confluence
was achieved with Ad4-H5-Vtn or wild-type (Ad4wt) viruses at a
concentration of 5610
8 vp/mL. The plates were incubated at
37uC and 5% CO2 for up to 72 hours with cells harvested at
multiple time-points and virus released using 3 freeze-thaw cycles.
To measure viral replication, the virus supernatant from each
time point was 10-fold serially diluted and 50 mL of each dilution
Figure 1. Ad4-H5-Vtn vector design. The H5HA native coding sequence, with the polybasic domain removed (B), was derived from A/Vietnam/
1194/2004 influenza virus and inserted into the Ad4 virus E3 gene region. The Ad4 virus E3 24.8K, E3 6.3K and E3 29.7K genes were deleted to
accommodate the HA transgene and the splice acceptor site of E3 24.8K was retained to drive expression of the HA transgene. The E3A
polyadenylation signal sequence, derived from Ad5, was placed downstream of the HA coding sequence. The use of a shuttle plasmid encoding the
H5HA sequence and the Ad4 plasmid to obtain the final vaccine product is described in Materials and Methods.
doi:10.1371/journal.pone.0031177.g001
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with 10% FCS before the mixture was plated into individual wells
of 24-well plates (2610
5 cells/well; final virus dilutions, 1610
21 to
1610
26 in log 10 increments). The plates were incubated for
48 hours at 37uC and 5% CO2. Following incubation, the media
was aspirated and cells were dried in the hood for 5 minutes. Cells
were fixed with 0.5 mL ice-cold 100% methanol (Fisher Scientific,
Waltham, MA). The plates were incubated for 15 minutes at
220uC followed by removal of methanol by aspiration. The plates
were then washed 3 times with 0.5 mL PBS/1% BSA (Sigma-
Aldrich, St. Louis, MO) followed by addition of 0.25 mL of hexon-
specific primary mouse antibody (AbD Serotec, Raleigh, NC)
diluted 1:200 in PBS/1% BSA to each well and plates incubated
for 1 hour at 37uC. Wells were then washed three times with PBS/
1% BSA followed by addition of secondary rat anti-mouse HRP
antibody (Invitrogen, Carlsbad, CA) diluted 1:1000 in PBS/1%
BSA and incubated for 1 hour at 37uC. Following incubation,
plates were washed 3 times with PBS/1% BSA followed by
addition of 0.25 mL DAB substrate (Invitrogen) to each well and
plates incubated at RT for 10–20 minutes. Following incubation,
the DAB substrate was aspirated and three fields containing 5–50
brownish/black spots (positive signal) were counted and averaged.
The infectious units (IFU) per mL were calculated using the
following formula: IFU/mL=(Spots/Field)6(Fields/Well)4(Virus
Volume (mL)6(Dilution Factor).
Immunization of Mice and Influenza H5N1 reassortant
Virus Challenge
To study the immunogenicity and efficacy of the Ad4-H5-Vtn
vaccine, C57BL/66BALB/c F1 mice (Charles River, Wilmington,
MA) and the H5N1 reassortant virus (VNH5N1-PR8/CDC-RG,
CDC Atlanta, GA) were used. Virus inoculums were administered
intranasally (i.n.) to mice under light isoflurane (Baxter, Deerfield,
IL) anesthesia.
To establish Ad4 pre-existing immunity, 50 mL containing
1610
9 vp Ad4wt virus was administered i.n. to mice. Ad4
immunity was confirmed by measuring Ad4 neutralizing antibody
titers approximately one month following administration of Ad4wt
virus. The Ad4-H5-Vtn recombinant vector vaccine virus was
subsequently administered i.n. to groups of Ad4wt pre-immune
and naı ¨ve mice (15 mice per group) at the following dosages;
1610
9,1 610
8,1 610
7 and 1610
6 vp per mouse.
As a positive control, animals were immunized subcutaneously
with 15 mg of H5HA (A/Vietnam/1203/2004) protein (Protein
Sciences, Meriden, CT) in PBS.
Each group was tested as follows: (1) Two mice (selected from
random groups) were euthanized one month post Ad4wt
immunization and pooled splenocytes used to complete Ad4
vector-specific IFN-c ELISPOT assays; (2) 2 mice/group were
euthanized one month post Ad4-H5-Vtn immunization and
splenocytes used to complete H5HA-specific IFN-c ELISPOT
assays; (3) 2 mice/group were euthanized 5 days post H5N1
reassortant virus challenge and splenocytes used to complete IFN-
c ELISPOT assays. Additionally, at this same time, lungs were
isolated and used to determine influenza viral titers; and (4) the
remaining 10 mice were evaluated for weight change and survival
for the duration of 14 days post challenge. Three random mice
from each group were bled six weeks following Ad4-H5-Vtn
vaccine immunization and again 5 days post influenza virus
challenge to determine hemagglutination inhibition (HAI) anti-
body titers.
Mice were challenged i.n. with a lethal dose (5 MLD50 of virus
in 50 mL) of the H5N1 reassortant virus 6 weeks post
immunization with Ad4-H5-Vtn vaccine virus. This dose insured
that a majority of the unvaccinated animals would not survive the
viral challenge.
Measurement of Ad4 Neutralizing Antibody Titer
Serial 5-fold dilutions of mouse immune serum (50 mL) were
mixed with 3.3610
6 vp of Ad4wt virus (50 mL) and incubated at
37uC for 2 hour. Titering of the virus was performed as described
for the one step growth curve analysis method. A 50% reduction of
number of infected cells compared to un-neutralized virus alone
equals the neutralization titer, expressed as reciprocal of dilution.
Measurement of Ad4 and H5 Hemagglutinin-Specific T
Cell Responses with an IFN-c ELISPOT Assay
T cell responses specific for; (1) Ad4 virus and (2) a ‘pool’ of A/
Vietnam/1194/2004 HA peptides were evaluated using an IFN-c
ELISPOT assay. Ad4 wt virus was heat inactivated for 1 hour at
72uC prior to use in the assay. The HA peptides in the pool
consisted of: HA.156, seq. KSSFFRNVVWLIKKN; HA.241 seq.
RMEFFWTILKPNDAI; HA.325 seq. NRLVLATGLRNSPQR;
and HA.529 seq. IYQILSIYSTVASSLALAI. The four HA-
derived peptides used in this study were selected based on
predicted high binding affinity to HLA-DR molecules using
algorithms from immunoepitope database (IEDB, www.iedb.org)
[42]. All peptides were purchased from A & A Labs LLC (San
Diego, CA). The purity of the peptides was substantiated by mass
spectrometry and generally found to be greater than 95%.
Peptides were dissolved in dimethyl sulfoxide at a concentration
of 20 mg/mL, stored frozen at 220uC, and diluted with PBS
before use.
Ninety-six well assay plates (MSIPS-4510, Millipore, Bedford,
MA) were coated with 10 mg/mL of a monoclonal antibody
specific for murine IFN-c (clone AN18, Mabtech, Stockholm) by
incubation overnight at 4uC. The antibody coated plates were
washed 6 times with PBS and blocked by adding RPMI-1640
containing 10% bovine serum and incubated for 1 hour at 37uC.
Unfractionated mouse splenocytes (5610
5) were added to
triplicate wells containing antigen (2610
9 Ad4wt vp per well or
0.4 mg of each HA-derived peptide per well) in a total volume of
0.2 mL per well. Plates were incubated for 24 hours at 37uC.
Wells were then washed 6 times with PBS containing 0.05%
Tween 20 (Sigma) followed by a 1 hour incubation with 100 mLo f
biotin-conjugated monoclonal antibody (1 mg/mL final) specific
for murine IFN-c (clone R4-6A2, Mabtech) diluted in PBS
containing 0.5% BSA (Sigma). Plates were washed 6 times with
PBS 0.05% Tween 20 before adding 100 mL of an avidin-
peroxidase complex (eBioscience, San Diego, CA), diluted in PBS
containing 0.5% BSA, was added to each well and incubated for
1 hour at room temperature. The plates were washed 6 times with
PBS containing 0.05% Tween 20 and 3 times with PBS. AEC
peroxidase substrate solution (100 mL) (Vector Laboratories Inc.,
Burlingame, CA) was used as the color development substrate,
which was stopped after 5 minutes with the addition of water.
Spots were counted using a CTL S5 Core plate reader (Cellular
Technologies Ltd, Shaker Hts, OH) and data defined as numbers
of spot forming cells (SFC) per 1610
6 splenocytes 6 the standard
deviation for each peptide. The limit of quantitation for the
ELISPOT assay was established as 50 SFC/10
6 splenocytes, a cut-
off similar to values described by other investigators [43].
Hemagglutination Inhibition (HAI)
HAI was performed by incubating with 4 HA units of the H5N1
reassortant virus in the presence of serially diluted sera, previously
treated overnight with receptor destroying enzyme, RDE
Ad4 H5HA Avian Influenza Vaccine Development
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stable non-specific inhibitors in duplicate wells of a 96 well plate
for 30 minutes at RT. Chicken RBCs (Charles River Laboratories,
Wilmington, MA) were then added and plates incubated for an
additional 30 minutes. Plates were tilted and then visually
inspected for agglutination. The reciprocal of the highest dilution
of antibody that causes inhibition of hemagglutination was
considered the HAI titer.
Influenza Viral Titer Measurement from Mouse Lungs
To assess the clearance of H5N1 reassortant influenza challenge
virus from the lungs, 2 mice from each group were euthanized 5
days post viral challenge and lungs were harvested for use. Lungs
were snap frozen on dry ice with ethanol and stored at 270uC.
Lungs were thawed and then homogenized with a FastPrep-24
tissue homogenizer (VDI 12 Tissue Homogenizer, VWR Interna-
tional) in 1 mL PBS per lung. Tissue homogenates were clarified
by centrifugation (10,0006g), the supernatant was filtered and 6
replicates of 5-fold serial dilutions of supernatant were added to
96-well plates containing MDCK cells (ATCC #CCL-34). Plates
were cultured at 37uC and 5% CO2. Following 18 hour
incubation, the presence of anti-influenza nucleoprotein NP was
determined using a modified ELISA protocol. Media was
discarded and cells were washed once with PBS then fixed with
80% methanol. Wells were then washed with PBS containing
0.05% Tween 20 and anti-NP antibody (Chemicon, Temecula,
CA) added followed by 1 hour incubation at room temperature.
After thorough washing, NP-specific antibodies were detected by
incubating for 1 hour with a goat anti-mouse IgG HRP-coupled
secondary antibody (Invitrogen). The plates were developed with
TMB HRP substrate reagent, stopped with acid, and absorbance
measured on a PolarStar plate reader at 450 nm. Lung viral titers
were calculated as TCID50/mL according to the Reed and
Muench method [44].
Statistical Analysis
ELISPOT: the Student t test was used to compare the immune
response between immunized vs. naı ¨ve (non-immunized) mice as
well as for the impact of pre-existing immunity. A p value of ,0.05
was used as the indication of significant responses. Additionally, to
be considered a positive response, a minimum of 50 IFN-c SFC
had to be achieved.
Survival: Statistically significant differences in survival times
were established using the Fisher’s exact test analysis. Differences
were considered statistically significant if the p value was ,0.05.
Results
Ad4-H5-Vtn Virus Generation
The Ad4-H5-Vtn virus was generated in A549 cells, with CPE
appearing only a few days delayed compared to an Ad4wt control.
Extraction of the viral DNA and restriction digestion mapping
with several combinations of enzymes confirmed at a gross level
that the viral genome was intact without major deletions or
insertions (data not shown). PCR across the E3 region (including
the expression cassette) generated a DNA product of the correct
size and sequencing of the PCR product confirmed the sequence
of the recombinant E3 region (data not shown). Similar analysis
was performed after 5, 10 and 15 serial passages in A549 cells and
confirmed that the viral genome was genetically stable (data not
shown).
Protein expression of H5-Vtn HA was evaluated from A549
cells infected with the recombinant virus by both western and flow
cytometry. Western analysis confirmed that Ad4-H5-Vtn infected
A549 cells robustly expressed HA protein of the correct 80 kDa
size similar to purified recombinant (r)H5 protein positive controls
(Figure 2A). Minor bands were also observed corresponding to
HA1 and HA2, cleavage products of full-length HA0. Specificity of
the antibody was affirmed by the lack of cross reactivity in the
uninfected A549 cells negative control.
Flow cytometry confirmed that the expressed HA was present
on the cell surface of Ad4-H5-Vtn-infected A549 cells (Figure 2B)
and that mean fluorescence intensity (MFI) increased in a dose-
dependent manner. Specifically, the following MFIs were
observed: 5610
6 vp/mL (6.0 MFI); 5610
7 vp/mL (13.1 MFI);
5610
8 vp/mL (34.0 MFI). As a negative control, A549 cells
infected with Ad4wt virus resulted in an MFI of 2.2.
Ad4-H5-Vtn Virus Growth is Attenuated Relative to
Ad4wt Virus
Conventional animal vaccine safety studies are not informative
for the Ad4-H5-Vtn vaccine as Ad4 is species specific and will not
replicate in non-human species. Thus, we compared the growth of
Ad4-H5-Vtn virus to Ad4wt virus in several human cell lines;
A549, Hu Tu 80, MRC-5, H1299 and HepG2. Growth and
replication rate of Ad4-H5-Vtn virus were similar or attenuated
relative to Ad4wt virus. Specifically, when evaluating the 48 hour
time points following cell infection, the burst sizes were
comparable (Hu Tu 80, MRC-5) to 1.8- to 2.7-fold lower
(H1299, HepG2, A549) for Ad4-H5-Vtn virus in the cell lines
tested (Figure 3). At the 72 hour time point, Ad4-H5-Vtn virus was
approximately 1.1- to 1.7-fold lower in burst size relative to Ad4wt
Figure 2. Ad4-H5-Vtn virus infection of A549 cells induced H5
HA protein expression as detected by Western blot and flow
cytometry analysis. In the case of western blot analysis (A), A549 cells
were infected in suspension with clarified crude lysate of Ad4-H5-Vtn
virus from the 14
th passage. The cell extracts, 2.5% and 5%, were
subjected to SDS-PAGE in 4–12% Bis-Tris gel, blotted onto nitrocellulose
membrane and probed with anti-1194 H5HA polyclonal sheep
antibody. Lysates as indicated, from uninfected A549 cells were used
as negative control. Recombinant His tagged H5HA1203/2004 100 ng
and 200 ng proteins were used as positive controls. b-actin was used as
loading control. HA0 refers to full length H5HA; HA1 and HA2 represent
the proteolytically cleaved form of HA. In the case of flow cytometry (B),
A549 cells were infected with a dose titration (vp/mL) of the Ad4-H5-
Vtn vector: dotted line, 5610
6; solid line, 5610
7; dashed line, 5610
8.
Infected cells were removed and subsequently incubated with primary
anti-H5HA and secondary goat anti-IgG PE antibodies. A negative
control, A549 cells infected with Ad4wt virus (5610
8 vp/mL) was
included; grey fill.
doi:10.1371/journal.pone.0031177.g002
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virus higher than that of Ad4wt virus.
Vaccine-Induced H5HA-specific Humoral Response in the
Presence and Absence of Pre-existing Ad4-specific
Immunity
To evaluate the effect of pre-existing immunity to Ad4wt virus
on vaccine potency, mice were immunized i.n. with 1610
9 vp of
Ad4wt virus and one month later Ad4-specific neutralizing
antibody titers and cellular immunity were determined. Immune
sera from 10 immunized mice were collected and Ad4-specific
neutralizing antibody titers measured. Titers ranged from 133 to
3,140 with a geometric mean of 569 (Figure 4A). Sera from naı ¨ve
mice exhibited values of ,10 for neutralizing antibody titers (data
not shown). Mice demonstrating pre-existing Ad4wt immunity and
naı ¨ve mice were subsequently used for Ad4-H5-Vtn vaccine
immunizations. Naı ¨ve mice exhibited higher HAI antibody titer
trends relative to mice with pre-existing immunity to Ad4wt
vector: 40 vs. 20; 20 vs. ,10; and 10 vs. ,10 for 10
9,1 0
8 and
10
7 vp Ad4-H5-Vtn vaccine doses, respectively (Figure 4B, open
bars). Following the H5N1 reassortant virus challenge, HAI
responses were typically boosted higher by one dilution (Figure 4B,
black fill bar). The lowest dose of vaccine, 10
6 vp, was not
immunogenic, i.e., ,10 HAI antibody titer. As comparator
controls, mice immunized with 15 mg of recombinant H5HA
protein induced 10 and 20 HAI antibody titers pre- and post-
H5N1 reassortant virus challenge. Significant HAI antibody titers,
5 days post virus challenge, were not detected in mice immunized
with only Ad4wt virus and subsequently challenged with H5N1
reassortant virus.
Vaccine-Induced H5HA-specific Cellular Response in the
Presence and Absence of Pre-existing Ad4-specific
Immunity
Significant Ad4-specific cellular immunity (140 IFN-c spot
forming cells (SFC) per 1610
6 splenocytes) against heat-inactivat-
Figure 3. Ad4-H5-Vtn virus growth is attenuated in various human cell lines versus Ad4wt virus. Growth of Ad4-H5-Vtn virus was
compared to growth of Ad4wt virus in several human cell lines: A549 a lung carcinoma cell line (A); Hu Tu 80 a duodenum adenocarcinoma cell line
(B); MRC-5 an embryonic lung fibroblast cell line (C); H1299 a lung carcinoma line (D); and HepG2 a hepatocellular carcinoma cell line (E). Virus
infection and cell growth conditions are described in Materials and Methods.
doi:10.1371/journal.pone.0031177.g003
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splenocytes from naive mice (Figure 5A). Pre-existing Ad4wt
immunity also affected vaccine induction of cellular immunity,
specific for a pool of four 15-mer peptides derived from the A/
Vietnam/1194/2004 HA protein (Figure 5B, open bar). Gener-
ally, naı ¨ve mice exhibited significantly higher H5HA-specific
cellular immune responses (SFC) relative to mice with pre-existing
immunity to Ad4wt vector: 200 vs. 100; 120 vs. ,50; and 80 vs.
,50 for 10
9,1 0
8 and 10
7 vp Ad4-H5-Vtn vaccine doses,
respectively (Figure 5B, open bar). Cellular responses were
augmented 5 days following H5N1 reassortant virus challenge.
In the presence or absence of pre-existing Ad4wt immunity, 10
7,
10
8,1 0
9 vp doses of Ad4-H5-Vtn vaccine induced between 300
and 600 IFN-c SFC (Figure 5B, black fill bar). It should be noted
that in the case of pre-existing Ad4wt immunity and vaccine doses
of 10
7 and 10
8 vp, minimal non-significant IFN-c responses of
,50 SFC were boosted to .500 SFC following H5N1 reassort-
ment virus challenge suggesting that even the lower vaccine doses
primed for cellular responses. The 10
6 vp dose was not
immunogenic, i.e., ,50 SFC. As comparator controls, mice
immunized with 15 mg of recombinant H5HA protein induced
80 and 680 IFN-c SFC post-immunization and post-H5N1
reassortant virus challenge, respectively. Significant HA-specific
cellular responses, 5 days post H5N1 reassortant virus challenge,
were not detected in mice immunized with only Ad4wt virus.
Efficacy of the Ad4-H5-Vtn Vaccine: Weight Loss, Survival
and Reduction of Lung Influenza Virus Titers
Weight loss, survival and reduction of lung influenza virus titers
were vaccine dose dependent following lethal H5N1 reassortant
virus challenge. Weights of the animals were measured for 14 days
following H5N1 reassortant challenge (Figure 6A). In animals
without pre-existing Ad4-specific immunity little to no weight loss
was observed at the 10
7,1 0
8 and 10
9 vp Ad4-H5-Vtn vaccine
doses. Ad4wt pre-existing immunity could be overcome and
Figure 4. Vaccine-induced H5HA-specific humoral response in
the presence and absence of pre-existing Ad4-specific immu-
nity. Mice were immunized i.n. with 1610
9 vp of Ad4wt virus per
mouse to establish pre-existing immunity to the vector. Four weeks
following the immunization, ten individual mice were bled and Ad4-
specific neutralizing antibody titers were determined (A). Mice
immunized with Ad4wt virus and naı ¨ve mice were subsequently
immunized i.n. with a dose titration of the Ad4-H5-Vtn vaccine; 1610
9,
1610
8,1 610
7 and 1610
6 vp per mouse and bled 6 weeks after vaccine
immunization and again 5 days later following H5N1 reassortant virus
challenge to determine HAI antibody titers (B). The immune responses
are represented by post-Ad4-H5-Vtn vaccine immunization (open bar)
and post-H5N1 reassortant challenge (cumulative of open and black fill
bar). Three mice from the group were bled and sera pooled to
determine HAI antibody titers.
doi:10.1371/journal.pone.0031177.g004
Figure 5. Vaccine-induced H5HA-specific cellular response in
the presence and absence of pre-existing Ad4-specific immu-
nity. Mice were immunized i.n. with 1610
9 vp of Ad4wt virus per
mouse to establish pre-existing immunity to the vector as previously
stated. Two mice were sacrificed and splenocytes pooled to determine
Ad4wt virus-specific cellular immunity, as assayed by IFN-c ELISPOT (A).
Two mice were also sacrificed 6 weeks after vaccine immunization and
again 5 days later following H5N1 reassortant virus challenge and
splenocytes pooled to determine H5 HA-specific cellular immunity
evaluated by IFN-c ELISPOT specific for four H5HA-derived 15-mer
peptides, stimulating peptides for ELISPOT response (B). In the case of
part (B), the immune responses are represented by post-Ad4-H5-Vtn
vaccine immunization (open bar) and post-H5N1 reassortant challenge
(cumulative of open and black fill bar). Mice pre-treated with Ad4wt
virus and challenged with H5N1 reassortant virus demonstrated no
detectable H5HA-specific cellular responses 5 days post-influenza virus
challenge. An asterisk * denotes significant IFN-c responses, p,0.05. In
the case of two asterisks (*/*) associated with a bar, the bottom and top
asterisks refer to post-immunization and post-reassortant H5N1 virus
challenge, respectively.
doi:10.1371/journal.pone.0031177.g005
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dose of 10
9 vp. Mice immunized with recombinant H5HA protein
lost no weight while Ad4wt immunized mice succumbed to
disease.
Survival of mice is shown in Figure 6B. Groups of mice
receiving 10
8 and 10
9 vp of vaccine were completely protected
(p=0.0001). Note that pre-existing immunity to Ad4wt virus did
not affect animal survival at these doses. However, at lower
vaccine dose of 10
7 vp, the vaccine was not as effective in the
presence of pre-existing immunity (p=0.0031). The lowest vaccine
dose of 10
6 vp was not protective regardless of Ad4 pre-immune
status and the use of Ad4wt virus without the H5HA transgene did
not protect animals.
Lungs from two mice representing each group were obtained 5
days post-H5N1 reassortant virus challenge to evaluate influenza
virus titer (Figure 7). Protection against influenza virus challenge
was most evident in the mice immunized at the higher vaccine
dose of 10
9 vp and mice immunized with H5HA protein where a
measurable influenza virus titer was not obtained from lungs. In
contrast, lungs from negative control mice immunized with Ad4wt
virus and mice immunized with the lower vaccine dose of 10
6 vp
generated a virus titer of approximately 4,000 TCID50/mL. At the
vaccine dose of 10
8 vp, an approximate 8- to 31-fold reduction in
virus titer was observed. Effects of pre-existing immunity to Ad4wt
virus was most evident at the lower vaccine dose of 10
7 vp where
an approximate 44-fold and 1.5-fold reduction of virus was
observed in the absence and presence of pre-existing immunity.
Discussion
The efforts of the study were to design, produce, and evaluate
for safety, immunogenicity and efficacy a recombinant replicating
Ad4 virus encoding the H5HA gene from avian influenza H5N1
strain, A/Vietnam/1194/2004, as a prototype vaccine. The Ad4-
H5-Vtn virus readily infected A549 cells and supported robust
expression of H5 HA protein, as demonstrated using western blot
and flow cytometry analyses. The Ad4-H5-Vtn virus was
attenuated in its growth capacity supporting an acceptable safety
profile.
Although human Ad4 viruses will not replicate, i.e., generate a
productive infection, in cells of nonhuman origin [15,18,45,46,47],
they will infect nonhuman cells presumably through the
evolutionarily conserved cocksackie and adenovirus receptor
(CAR) [48]. The infected cells of non-human origin will support
transcription and translation of both Ad4 vector and transgene
sequences. We took advantage of this property to assess vaccine
Figure 6. Mice immunized with Ad4-H5-Vtn vaccine lost no
weight, survived a lethal H5N1 reassortant viral challenge and
presented with a reduction of H5N1 reassortant virus in the
lungs. Groups of mice were immunized with Ad4wt virus to establish
pre-existing immunity as described previously in Materials and Methods
section. Mice were subsequently immunized intranasally with a dose
titration of the Ad4-H5-Vtn vaccine. Six weeks following Ad4-H5-Vtn
vaccine immunization, the mice were challenged with a lethal dose of
H5N1 reassortant virus. If animals were recorded to have lost 20% or
more of their original weight for two days in a row they were
euthanized. Weights of the mice were evaluated daily (A), and survival
of mice were evaluated over a 14 day period (B).
doi:10.1371/journal.pone.0031177.g006
Figure 7. Mice immunized with Ad4-H5-Vtn vaccine presented with a reduction of H5N1 reassortant virus in the lungs. Groups of
mice were immunized with Ad4wt virus to establish pre-existing immunity as previously described in Materials and Methods section. Mice were
subsequently immunized intranasally with a dose titration of the Ad4-H5-Vtn vaccine. Six weeks following Ad4-H5-Vtn vaccine immunization, the
mice were challenged with a lethal dose of H5N1 reassortant virus. Lungs were recovered from a subset of mice 5 days post-challenge to determine
influenza-specific viral titers.
doi:10.1371/journal.pone.0031177.g007
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Phase 1 clinical trial vaccine evaluation. The vector vaccine virus
induced H5HA-specific HAI antibody and cellular immune
responses after a single i.n. immunization of mice even in the
presence of pre-existing Ad4-specific neutralizing antibody. The
immune responses of vaccinated mice challenged with the H5N1/
PR8 reassortant virus five days post influenza virus challenge were
characterized by rapid increases of both H5HA-specific antibody
and cellular immune responses. We did not assess the individual
contribution of CD8
+ and CD4
+ T cells to the overall cellular
response. A study by Hoelscher and colleagues using a similar
vaccine approach demonstrated that mice immunized with a
recombinant adenovirus H5 HA vaccine induced an HA-518-
epitope-specific IFN-c-secreting CD8
+ T cell response [30]. In this
study, T cell responses specific for HA-derived 15-mer peptides
were measured. The peptides were selected on the basis of
predicted binding to HLA-DR molecules and therefore are
predicted to measure predominately CD4
+ T cell responses.
However, to formally address this issue, HA-specific cellular
responses induced by the Ad4-H5-Vtn vaccine will be evaluated
specifically for contributions of CD4
+ and CD8
+ T cell subsets in
the current ongoing Phase 1 trial. Vaccine-induced immune
responses afforded a significant level of protection against lethal
H5N1 reassortant virus challenge as measured by reduced weight
loss, survival and reduced influenza virus replication in the lungs.
It should be noted that a single time point of 5 days post influenza
virus challenge was evaluated for virus titer in the lungs. It was
concluded that mice immunized with the higher doses of Ad4-H5-
Vtn vaccine had a significantly lower virus titer relative to mice
immunized with the Ad4wt control. It is not known whether the
reduction in virus titer was due to accelerated viral clearance or
alternatively an initial lower virus load in the immunized animals.
Of particular note is that efficacy was also observed despite the
absence of measurable immune responses, which were character-
ized with anamnestic responses indicating the vaccine had primed
the immune system. The Ad4-H5-Vtn vaccine induction of
H5HA-specific humoral and cellular immunity generally correlat-
ed with efficacy. Pre-existing immunity to the Ad4wt vector did
have an effect on both immunogenicity and efficacy but the effect
was more pronounced at the lower vaccine doses suggesting that
pre-existing immunity to the Ad vector may be overcome by using
higher vaccine doses.
We selected the replicating Ad4 virus and mucosal route of
administration for several reasons including: 1) safety and efficacy
as documented by the U.S. Military Ad4 vaccine program; 2)
potential use of lower doses due to replication competence; 3)
induction of potent innate and adaptive immune system
responses; 4) induction of immunological memory 5) a means
to minimize effects of pre-existing immunity to the vector; and 6)
capacity via molecular methods to readily generate new Ad4
vector-based vaccines expressing disease transgenes of interest
[8,21,28,37,38,39,40,49,50,51,52,53,54,55,56,57,58]. In addi-
tion, we have the capacity to quickly change the HA to address
an emerging H5N1 threat from around the globe. Several
agencies including the World Health Organization monitor cases
around the world and are able to detect new species in both
domestic and wild bird populations as well as any documented
human cases.
We designed the influenza vaccine using an insertion site for
HA in the non-essential E3 region to preserve virus replication in
human cells. In contrast, a majority of recombinant Ad vector
vaccine development to date has relied on Ad5 vector which will
not replicate in humans due to modification of the replication
essential E1 region.
There are possible limitations for the use of Ad-based vaccines,
most notably potential lack of vaccine potency due to pre-existing
immunity. Pre-existing immunity may be derived from natural
infection or repeated Ad-based vaccine immunization. As reported,
the overall prevalence for Ad4 neutralizing antibodies is approx-
imately 30% [59]. Weevaluated theeffects ofpre-existingimmunity
experimentally. Our initial task was to establish Ad4-specific pre-
existing immunity in mice to a level typically observed in man.
Lyons and colleagues reported in a recent study of the Ad4 (and
Ad7) vaccine during a period ongoing Ad4wt transmission and
disease, that 36 individuals with pre-existing immunity to Ad4 virus
demonstrated neutralizing antibody titers corresponding to a range
of 12–724, with a geometric mean of 78 [53]. In the mouse studies,
described herein, the Ad4-specific neutralizing antibodies induced
following Ad4wt immunization were higher with a range of 133–
3140, and a geometric mean of 569. Thus, it is likely that Ad4
responses induced in our animal system were at least comparable or
higherthanthoseobservedinman.Usingthisexperimentalvariable
weobserved the administration ofhigher vaccinedosesandmucosal
delivery are sufficient to overcome the effects of pre-existing
immunity, an observation consistent with numerous reports
[49,51,52,54,55,57,58]. Data from several human studies support
this concept. For example, orally administered replicating rotavirus
vaccines induce an antibody response in infants who have pre-
existing rotavirus antibody [60]. Recent experience with the Ad
serotype 4 (Ad4) and Ad serotype 7 (Ad7) vaccines suggests that pre-
existing Ad4 or Ad7 neutralizing antibody did not prevent
replication or an immune response induced by the vaccine,
although it may have diminished it [53].
In summary, these data support further evaluation of the live,
replication-competent, recombinant Ad4 candidate vaccine, which
expresses the HA of H5N1 A/Vietnam/1194/2004 influenza
virus in a Phase 1 clinical trial. It is hypothesized that an orally
administered enteric-coated capsule containing Ad4-H5-Vtn virus
will release the virus in the intestine, replicate, express H5HA, and
elicit a humoral and cellular immune response that will be
protective against H5N1 influenza. A first-in-man, Phase 1 double-
blind, placebo controlled ascending dosage study is currently in-
progress in which 166 volunteers (vaccine:placebo=3:1) have
been given escalating dosages of this Ad4-H5-Vtn vaccine (10
7,
10
8,1 0
9,1 0
10 and 10
11 vp total dose). The final drug product was
generated by lyophilizing purified Ad4-H5-Vtn (produced in
MRC-5 under GMP conditions) into a dry powder form. The dry
virus was then adjusted to the desired dosage concentration using
dry sucrose excipient, filled into hydroxypropylmethylcellulose
(HPMC) capsules, and enteric-coated. The primary objectives of
the clinical study are to evaluate safety and humoral immunoge-
nicity following oral administration of the vaccine. Additional
objectives of this study are to evaluate the mucosal and cellular
immune responses to the influenza H5HA antigen, investigate the
replication and excretion (shedding) of the Ad4-H5-Vtn virus, and
evaluate the effect of pre-existing immunity to Ad4 on these
parameters.
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